Biotech startups don't get far without doing something that's never been done before. For NovaDigm Therapeutics, the big first in the company's pipeline is a vaccine that could spur immunity against infections from both fungal Candida and bacterial Staphylococcus aureus, including the MRSA superbug. Tim Cooke, the company's CEO, is gearing up for a Phase II study in patients with vaginal Candida infections. Domain Associates has been its only venture investor to date and contributed $10 million, but Cooke is out talking to additional VCs this week about raising more money to bankroll development of an earlier-stage vaccine candidate. It's a good David vs. Goliath story, because some of its chief competitors include Pfizer ($PFE), GlaxoSmithKline ($GSK) and Novartis ($NVS).